Related references
Note: Only part of the references are listed.Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial)
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2023)
Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2023)
Ozoralizumab for rheumatoid arthritis
Jennifer Thorley
LANCET RHEUMATOLOGY (2022)
Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis
Tsutomu Takeuchi et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
Stephane Paul et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe
Danka Svecova et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura
Maria Laura Sargentini-Maier et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Nanobody approval gives domain antibodies a boost
Chris Morrison
NATURE REVIEWS DRUG DISCOVERY (2019)
Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics
Alessandro Zorzi et al.
MEDCHEMCOMM (2019)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Cytokines in rheumatoid arthritis - shaping the immunological landscape
Iain B. McInnes et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2016)
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
Maarten Van Roy et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and MetaAnalysis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies®
Sven Hoefman et al.
ANTIBODIES (2015)
Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study
Tsutomu Takeuchi et al.
Modern Rheumatology (2014)
Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
Takuo Suzuki et al.
JOURNAL OF IMMUNOLOGY (2010)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis
Honghui Zhou et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Formatted anti-tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis
Ken Coppieters et al.
ARTHRITIS AND RHEUMATISM (2006)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
